Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (35)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bajetta, E.
Right arrow Articles by Bombardieri, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bajetta, E.
Right arrow Articles by Bombardieri, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:614-621, 2002
© 2002 European Society for Medical Oncology

Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours

E. Bajetta1,+, L. Ferrari2, G. Procopio1, L. Catena1, E. Ferrario1, A. Martinetti2, M. Di Bartolomeo1, R. Buzzoni1, L. Celio1, M. Vitali1, E. Beretta1, E. Seregni2 and E. Bombardieri2,§

1Medical Oncology Unit B and 2Nuclear Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori di Milano (INT), Milano, Italy

Received 8 May 2001; revised 14 September 2001; accepted 25 September 2001.

Objectives

Neuroendocrine tumours (NETs) are heterogeneous neoplasms for which there is no standard treatment. We have previously proposed an effective polychemotherapy (5-fluorouracil, dacarbazine and epirubicin), which only produced objective responses of brief duration. The present study aimed to assess in a multidisciplinary manner the efficacy of the same regimen at intensified doses in patients with advanced NETs.

Patients and methods

Eighty-two consecutive patients entered the study, of whom 21 had inoperable, locally advanced disease and 61 had metastatic disease. Seventy-two patients were evaluated for objective, biochemical and subjective responses. Response rate, time to progression (TTP) and overall survival (OS) were evaluated based on histotype.

Results

An objective response was observed in 20 patients (intention-to-treat and standard analysis 24.4% and 27.8%, respectively). Complete biochemical and subjective responses were obtained in 25.1% and 38.9% of the cases. The median duration of treatment was 4 months and the objective responses had a median duration of 38 months. After a 60-month follow-up the median TTP and OS were 21 and 38 months, respectively.

Conclusions

Our polychemotherapy regimen is effective, with long duration, and is well tolerated both for gastroenteropancreatic and lung NETs, as well as for tumours with a more aggressive clinical behaviour. The new WHO endocrine tumour histotyping, examining also the tumour biology, may give additional information for selecting patients to chemotherapy.

Key words: chemotherapy, chromogranin A, metastatic disease, neuroendocrine tumours


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
K. Oberg, S. Jelic, and On behalf of the ESMO Guidelines Working Group
Neuroendocrine gastroenteropancreatic tumors: ESMO Clinical Recommendation for diagnosis, treatment and follow-up
Ann. Onc., May 1, 2009; 20(suppl_4): iv150 - iv153.
[Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
E. Vilar, R. Salazar, J. Perez-Garcia, J. Cortes, K. Oberg, and J. Tabernero
Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors
Endocr. Relat. Cancer, June 1, 2007; 14(2): 221 - 232.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
T. Konishi, T. Watanabe, J. Kishimoto, K. Kotake, T. Muto, H. Nagawa, and on behalf of the Japanese Society for Cancer of th
Prognosis and risk factors of metastasis in colorectal carcinoids: results of a nationwide registry over 15 years
Gut, June 1, 2007; 56(6): 863 - 868.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Ekeblad, A. Sundin, E. T. Janson, S. Welin, D. Granberg, H. Kindmark, K. Dunder, G. Kozlovacki, H. Orlefors, M. Sigurd, et al.
Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors
Clin. Cancer Res., May 15, 2007; 13(10): 2986 - 2991.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Bajetta, L. Catena, G. Procopio, E. Bichisao, L. Ferrari, S. Della Torre, S. De Dosso, S. Iacobelli, R. Buzzoni, L. Mariani, et al.
Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment?
Ann. Onc., August 1, 2005; 16(8): 1374 - 1380.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
J K Ramage, A H G Davies, J Ardill, N Bax, M Caplin, A Grossman, R Hawkins, A M McNicol, N Reed, R Sutton, et al.
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours
Gut, June 1, 2005; 54(suppl_4): iv1 - iv16.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.